Neuroschistosomiasis (NS) is a serious ectopic complication of schistosomiasis caused by Schistosoma mansoniwhose most common presentation is schistosomal myeloradiculopathy (SMR)1–3. Clinically, NS is associated with meningeal myeloradicular compromise, paraparesis, flaccid paraplegia with loss of reflexes and sensation in the lower half of the body, paresthesia in sacral regions 1 and 5, and bladder and rectal sphincter abnormalities, causing urinary and intestinal dysfunction, as well as sexual impotence in men4–6.
The most common urological symptoms of SMR are urinary retention and incontinence, which are potential causes of chronic bladder dysfunction. Further complications include urinary tract infection, hydronephrosis, formation of upper tract stones, and renal failure7.
Urodynamic study is the most important complementary exam used in clinical practice for investigating the causes of voiding dysfunction. Urodynamic study is the propaedeutic method for diagnosing lower urinary tract dysfunction, assessing bladder filling and emptying activity, and identifying the risk for upper urinary tract damage8.
This study aimed to identify the prevalence of urodynamic changes associated with risk for upper urinary tract damage in neuroschistosomiasis patients.
A prospective study was carried out at the Urology Outpatient Clinic between March 2014 and November 2015. The population was comprised of 68 patients, including 31 (46%) women and 37 (54%) men with voiding dysfunction and previous diagnosis of neuroschistosomiasis.
The prior diagnosis of neuroschistosomiasis was based on clinical presentation, neurological examination, testing for S. mansoni eggs in feces or by rectal biopsy, CSF exam, immunofluorescence for schistosomiasis, and spinal MRI. All patients reported a history of exposure to S. mansoni and had the chronic form of the disease.
Neuroschistosomiasis patients of both sexes experiencing voiding dysfunction were included in the study. Volunteers with a history of diabetes, chronic renal failure, resistant arterial hypertension, anatomic bladder obstruction, prior surgery of the bladder and pelvis, men with a prostate weighing ≥ 40g on ultrasound, urinary tract infection, and a history of neurological diseases unrelated to schistosomiasis were excluded.
All patients had the chronic form of the disease with neurological and urological symptoms. Previously they underwent urological assessment, including anamnesis, and physical examination. The following examinations were also performed: urine type I, urine culture, serum urea and creatinine levels, urodynamic study, and ultrasound of the upper and lower urinary tracts and prostate (in males).
Urodynamics define the diagnosis of lower urinary tract dysfunction. The important criteria in this evaluation are measurements of pressure and flow at the leakage point. This analysis was performed using a Dynamed® UroMaster II device and the following variables were analyzed: detrusor overactivity, bladder compliance, bladder areflexia, and bladder capacity and sensitivity.
Statistical analyses were performed using descriptive analysis and the z-test was performed for comparing proportionality between the two groups of patients. The two groups were subsequently subdivided based on risk for upper urinary tract damage. A p-value <0.05 was considered statistically significant, and all calculations were performed using Excel for Windows software.
The project was approved by the Research Ethics Committee of the Center. All volunteers previously signed the free and informed consent form.
Patient ages ranged from 21 to 71 years, and the mean age was 44.5 ± 13.0 and 50.6 ± 12.6 years in the groups with and without risk for upper urinary tract damage (UUTD), respectively. Statistical comparison of the groups (Student´s t-test) indicated that age had no effect on risk for UUTD (p = 0.880).
In relation to kidney function, the mean levels of urea and creatinine were: 36.3 mg/dl and 0.82 mg/dl for groups with and without risk of UUTD, respectively (Figure 1). The uroculture was positive for E. Coli in 16 patients (24%), but they had no symptoms of urinary infections and were submitted to the urodynamic study while taking prophylactic antibiotics. The abnormalities found in the urodynamic tests are shown in Table 1. Among the variables studied, detrusor overactivity was the most frequent urodynamic symptom found (69.1%).
FIGURE 1: The graph shows the urea and creatinine levels calculated to assess the function of kidneys.
| Variable | N | % |
|---|---|---|
| • Bladder capacity (ml) | ||
| Increased (> 600) | 13 | 19.1 |
| Normal (300-600) | 25 | 36.8 |
| Low (< 300) | 30 | 44.1 |
| • Compliance (ml/cmH20) | ||
| Increased (>80) | 04 | 5.8 |
| Normal (20-80) | 32 | 47.1 |
| Low (<20) | 32 | 47.1 |
| • Sensitivity (ml) | ||
| Low (>300) | 15 | 22.0 |
| Normal (100-300) | 13 | 19.1 |
| Increased (<100) | 32 | 47.1 |
| Absent (0) | 08 | 11.8 |
| • Cystometry | ||
| Detrusor overactivity | 47 | 69.1 |
| – No urine loss | 17 | 36.2 |
| – Urine loss | 30 | 63.8 |
| Stable detrusora | 21 | 30.9 |
| • Pressure-flow study | ||
| Areflexia | 19 | 27.9 |
| Normal | 10 | 14.7 |
| Detrusor sphincter dyssynergia | 31 | 45.6 |
| Detrusor hypocontractility | 08 | 11.7 |
| • Post-void residual urine (ml) | ||
| <100 | 32 | 47.1 |
| >100 | 36 | 52.9 |
The mean volume of residual urine after voiding was 249.0ml (range 0-1.560ml). Forty patients had one or more urodynamic change associated with risk for UUTD. Patients were subdivided into two groups based on risk for UUTD. (Table 2), Associations between the risk for UUTD and low compliance (p = 0.001) or low cystometric capacity (p = 0.002) were detected. Analysis of the other changes like different kinds of symptoms and detrusor activity were not had relationship with the risk for UUTD.
TABLE 2: Urodynamic changes in patients with and without risk for upper urinary tract damage.
| Urodynamic Changes | Risk for UUTD | p-value | |
|---|---|---|---|
| Present | Absent | ||
| N= 40 | N= 28 | ||
| Storage symptoms | 22 (55.0) | 14 (50.0) | 0.6841 |
| Voiding symptoms | 16 (40.0) | 13 (46.6) | 0.5981 |
| Mixed symptoms | 2 (5.0) | 1(3.6) | 1.0001 |
| Low compliance | 29 (72.5) | 3 (10.7) | 0.0011 |
| Low cystometric capacity | 24 (60.0) | 6 (21.4) | 0.0021 |
| Detrusor areflexia | 9 (22.5) | 10 (37.7) | 0.1171 |
| Detrusor overactivity | 31 (77.5) | 16 (57.1) | 0.0741 |
Upper urinary tract damage is the leading urological complication in patients with NS. Consequently, the main objective of urological treatment in these patients is protecting the upper urinary tract and promoting normal storage and voiding9–11.
Urinary incontinence and other storage symptoms were the main complaints identified in the present study. Similar complaints were described by Guinetet al.8, although other studies have reported a higher incidence of voiding symptoms.
Detrusor overactivity was the most common urodynamic symptom found in the present study, affecting 47 patients. In this group, 31 (77.5%) had detrusor-sphincter dyssynergia, where in 12 (38.7%) cases exhibited high detrusor overactivity without urine loss and 19 (61.3%) cases exhibited detrusor overactivity with low urine loss and consequent high post-void residual urine. These findings are consistent with the physiopathology of SMR, mainly because the upper spinal cord segments are spared, suggesting greater sacral involvement4–7.
Of the 19 patients with detrusor areflexia, 9 had urodynamic changes associated with risk for renal function deterioration.
This finding is similar with those of previous studies, which reported that a large number of patients with areflexia develop UTD 12–14.
Scientific evidence shows discordance between clinical and urodynamic diagnoses. For this reason the urodinamic study is very important for to use a specifc treatment and, to avoid incorrect diagnosis13–14.
The results of the present study showed a high prevalence of urodynamic changes associated with risk for upper urinary tract damage in neuroschistosomiasis patients. However, further studies involving larger samples are needed to confirm these findings.
